Send to

Choose Destination
Schizophr Res. 2017 Dec 21. pii: S0920-9964(17)30729-6. doi: 10.1016/j.schres.2017.11.031. [Epub ahead of print]

The brief negative symptom scale (BNSS): Sensitivity to treatment effects.

Author information

University of Nevada, Reno School of Medicine, Reno, NV, USA. Electronic address:
PPRS Research, Inc., Groton, MA, USA.
Department of Psychology, University of Georgia, Athens, GA, USA.
Department of Psychiatry, Weill Cornell School of Medicine, USA.
ProPhase LLC, New York City, New York, USA.
Minerva Neurosciences, Inc., Waltham, MA, USA.


The Brief Negative Symptom Scale (BNSS) grew out of a recommendation by the NIMH-sponsored Consensus Development Conference on Negative Symptoms that a scale based on contemporary concepts be developed. We assessed sensitivity to change of the BNSS in a trial of MIN-101, which showed efficacy for negative symptoms (PANSS pentagonal model) at daily doses of 32 and 64mg/day. Using mixed-effects model for repeated measures, we examined change in BNSS total score and in the BNSS factors of anhedonia/avolition/asociality (AAA), and expressivity (EXP). Compared to placebo, the 64mg group (N=83) showed a significant decrease in BNSS total score (effect size d [ES] 0.56, p<0.01) and both factor scores (AAA ES=0.48, EXP ES=0.46, p<0.02 for both). Patients in the trial had minimal depression and positive symptom scores; covarying for disorganization, positive symptoms, or anxiety/depression did not cause a meaningful change in the significance of the BNSS total or factor scores in this group. The 32mg group (N=78) did not differ significantly from placebo (N=83) on BNSS total score (ES=0.33, p<0.09), AAA (ES=0.25, p<0.20) or EXP (ES=0.30, p<0.12) scores. These results demonstrate the BNSS is sensitive to change.


Factor analysis; Negative symptoms; Psychometrics; Schizophrenia; Treatment

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center